HIV Articles
Back
	Bictegravir with Pre-Existing NRTI Resistance       Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs - (07/25/19)   Keeping the Pressure on Archived NRTI Resistance: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Triple Therapy in Study 4030 - (07/25/19)   Previously Undocumented Pre-existing Resistance and Maintenance of Virologic Suppression in HIV-1 RNA-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) - (07/25/19)   Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women - (07/25/19)   Forgiveness of Antiretroviral Regimens: In Vitro HIV-1 Viral Breakthrough with 2-Drug versus 3-Drug Regimens Simulating Variable Adherence to Treatment - (07/23/19)   Switching to a Single-tablet Regimen of Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) from Dolutegravir plus Either F/TAF or F/TDF - (07/25/19)   Susceptibility to Bictegravir in Highly ARV Experienced Patients After INSTI Failure - (03/15/19)   BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS - (03/15/19)   High Level of Preexisting NRTI Resistance Prior to Switching to B/F/TAF: Study 4030 - (03/15/19)   Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance - (04/08/19)   BICTEGRAVIR CONCENTRATIONS AND VIRAL SUPPRESSION IN CSF of HIV-INFECTED PATIENTS - (03/14/19)           View Older Articles   Back to Top   www.natap.org